GlassScriptPhysician profile
Steven J Harris
NPI 1720298912
$4,641.88
in general payments reported to CMS, 2019-2025
24 companies · $278 in 2025
The $278 reported for 2025 was more than what 86% of Hospice and Palliative Medicine (Family Medicine) providers received nationally (typical 2025 total: $78.57).
See the full distribution for Hospice and Palliative Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $618 · 2021: $733 · 2022: $619 · 2023: $921 · 2024: $394 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $972.31 | 2019-2020 | |
| Abbvie INC. | $799.03 | 2019-2024 | |
| Qol Medical, LLC | $546.82 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.74 | 2019-2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $332.69 | 2021-2025 | Nuzyra, Xhance |
| Merck Sharp & Dohme LLC | $235.36 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $233.60 | 2021-2023 | |
| Bio Products Laboratory USA, INC. | $217.40 | 2021-2023 | Gammaplex, Coagadex |
| Mayne Pharma Commercial LLC | $159.15 | 2020-2022 | |
| Octapharma USA, INC. | $145.16 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Janssen Pharmaceuticals, INC | $85.10 | 2022-2023 | Spravato |
| Pfizer INC. | $66.67 | 2023-2024 | |
| Horizon Therapeutics Plc | $56.06 | 2019-2020 | |
| Shire North American Group INC | $50.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.99 | 2021-2023 | Hyqvia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31.74 | 2020-2021 | |
| Allergan, INC. | $30.74 | 2020-2021 | |
| Grifols USA, LLC | $29.68 | 2021 | |
| Aimmune Therapeutics, INC. | $26.64 | 2024 | |
| Alfasigma USA, INC. | $25.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.20 | 2021 | |
| Vyera Pharmaceuticals, LLC | $21.06 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.75 | 2022 | |
| Vivus LLC | $18.24 | 2023 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.